Easterly Investment Partners’s Pacira BioSciences PCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.66M	Buy	334,854 +83,000	+33%	+$1.84M	0.59%	48
2025 Q4	$6.52M	Buy	251,854 +2,745	+1%	+$65.3K	0.4%	66
2025 Q3	$6.42M	Buy	249,109 +79,038	+46%	+$1.94M	0.43%	68
2025 Q2	$4.06M	Buy	170,071 +57,900	+52%	+$1.46M	0.29%	86
2025 Q1	$2.79M	Buy	112,171 +6,520	+6%	+$156K	0.23%	97
2024 Q4	$1.99M	Sell	105,651 -28,833	-21%	-$506K	0.16%	116
2024 Q3	$2.02M	Buy	134,484 +28,928	+27%	+$495K	0.16%	118
2024 Q2	$3.02M	Buy	105,556 +26,235	+33%	+$747K	0.27%	95
2024 Q1	$2.32M	Buy	79,321 +23,877	+43%	+$734K	0.18%	112
2023 Q4	$1.87M	Buy	55,444 +17,594	+46%	+$515K	0.2%	113
2023 Q3	$1.16M	Buy	+37,850	New	+$1.36M	0.13%	127